Beyond weight loss, early exploratory data suggest potential benefits including: Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes Improvements in lipid profiles (cholesterol and triglycerides) Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary Possible cardiovascular benefits
[149] Derived from Table 2 available on [150] History [edit] Between 1849 and 1887, Thomas Addison described a case of pernicious anemia, William Osler and William Gardner first described a case of neuropathy, Hayem described large red cells in the peripheral blood in this condition, which he called "giant blood corpuscles" (now called macrocytes), Paul Ehrlich identified megaloblasts in the bone marrow, and Ludwig Lichtheim described a case of myelopathy
Lose weight or address body composition changes: Ask your clinician about GLP-1s (like semaglutide or tirzepatide), other meds like Contrave or metformin, supplements like berberine, and other lifestyle strategies
Reconstitution Best Practices: When reconstituting AOD-9604 , allow both the peptide vial and bacteriostatic water to reach room temperature to minimize temperature shock
